Composition for wound treatment comprising mast cell-conditioned medium

Composition for skin wound healing using mast cell-conditioned medium stimulated with FSL-1

This technology is a composition for the prevention and treatment of skin wounds that uses, as an active ingredient, a conditioned medium from mast cells stimulated with FSL-1, a Toll-like receptor 2 and 6 agonist. It can be formulated as pharmaceutical compositions, topical skin applications, and food products.

Mast cells have traditionally been known for exacerbating allergic diseases by releasing inflammatory substances like histamine. However, the fact that substances secreted by mast cells can promote the migration of skin keratinocytes and contribute to wound healing had not been established, and there were no prior applications of this as a wound treatment material.

This technology enhances the wound-healing capacity of mast cell-conditioned medium through FSL-1 stimulation. Components such as tryptase within the medium promote the migration of human skin keratinocytes, showing excellent recovery effects, particularly during the inflammatory phase. Since it uses culture-derived conditioned medium rather than direct cell transplantation, commercialization is relatively straightforward. It can be applied to treatments for burns, pressure ulcers, diabetic ulcers, and post-surgical wounds, as well as regenerative topical skin products, providing a new cell-derived therapeutic material for managing intractable wounds.

‍

‍

Key Features:

• Pharmaceutical composition for preventing or treating skin wounds comprising, as an active ingredient, a conditioned medium of mast cells pretreated with FSL-1, a Toll-like receptor 2 and 6 agonist
• Mast cell-conditioned medium obtained from human-derived mast cells, containing tryptase and promoting skin keratinocyte migration
• Pharmaceutical composition targeting various skin wounds, including burns, trauma, post-surgical wounds, pressure ulcers, diabetic ulcers, and radiation damage
• Topical skin composition for skin wound improvement and food composition for skin wound prevention, both containing FSL-1 pretreated mast cell-conditioned medium

‍

This invention was developed with support from the Ministry of Science and ICT for research into the mechanisms of lymphocyte migration and differentiation inhibition by cell therapeutics.

‍